Biotechnology company developing engineered T cell therapies for autoimmune diseases.
Cabaletta Bio, Inc. is a pioneering clinical-stage biotechnology company focused on advancing engineered T cell therapies specifically designed for patients grappling with B cell-mediated autoimmune diseases. Established in 2017 and based in Philadelphia, Pennsylvania, the company specializes in developing innovative treatments using its proprietary chimeric autoantibody receptor (CAAR) T cell technology. This groundbreaking approach aims to target and eliminate disease-causing B cells responsible for producing harmful autoantibodies.
At the forefront of Cabaletta Bio's portfolio is DSG3-CAART, its lead product candidate currently undergoing Phase I clinical trials. This therapy targets mucosal pemphigus vulgaris, a severe autoimmune blistering skin disease, as well as Hemophilia A with Factor VIII alloantibodies. Additionally, the company's pipeline includes MuSK-CAART, a promising preclinical treatment for a subset of patients suffering from myasthenia gravis, and FVIII-CAART, a discovery-stage therapy for addressing Hemophilia A.
Cabaletta Bio collaborates closely with esteemed institutions such as the University of Pennsylvania and The Regents of the University of California. These partnerships underscore the company's commitment to leveraging cutting-edge research and development strategies to advance therapeutic innovations in autoimmune disease treatment.
Formerly known as Tycho Therapeutics, Inc., Cabaletta Bio rebranded in August 2018 to reflect its focused mission and expanded capabilities in developing transformative CAAR T cell therapies. With its headquarters in Philadelphia, the company continues to push the boundaries of biotechnology, aiming to deliver life-changing therapies that address critical unmet needs in autoimmune disorders.